Literature DB >> 227265

Cytomegalovirus encephalitis associated with thymoma and immunoglobulin deficiency.

C A Kauffman, C C Linnemann, M M Alvira.   

Abstract

The clinical and immunologic findings in an elderly woman with thymoma and immunoglobulin deficiency in whom cytomegalovirus (CMV) encephalitis developed are described. The patient had absent serum immunoglobulins and no circulating immunoglobulin-bearing lymphocytes. Complement receptor-bearing lymphocytes were present in the peripheral blood, and circulating T lymphocyte numbers were within normal limits. She was anergic to a battery of skin test antigens, and her lymphocytes in vitro showed a selective unresponsiveness to CMV antigen while responding normally to phytohemagglutinin and streptokinase. The course of the encephalitis was progressive with quadriplegia, aphasia and coma developing within six months of onset of symptoms. This is the fifth reported case documenting an association between CMV infection and the syndrome of thymoma with immunoglobulin deficiency, but the first report of fatal CMV encephalitis in a patient with thymoma and immunoglobulin deficiency.

Entities:  

Mesh:

Year:  1979        PMID: 227265     DOI: 10.1016/0002-9343(79)90274-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

Review 1.  What is Good's syndrome? Immunological abnormalities in patients with thymoma.

Authors:  P Kelleher; S A Misbah
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

Review 2.  Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence.

Authors:  Theodoros Kelesidis; Otto Yang
Journal:  Clin Immunol       Date:  2010-02-10       Impact factor: 3.969

3.  Good's syndrome with opportunistic infection of the central nervous system: a case report.

Authors:  Shinichi Ueno; Satoko Sekimoto-Tsuboi; Yuta Ishiguro; Takahiro Koinuma; Hiroto Eguchi; Yutaka Machida; Nobutaka Hattori; Hideto Miwa
Journal:  BMC Neurol       Date:  2015-08-25       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.